Lancashire and South Cumbria
Formulary
Formulary
5 Infections
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-03-03 Viral hepatitis
| Adefovir Dipivoxil Hepsera® |
|
Formulary
|
Tablets 10mg
|
 NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B |
|
Specialist prescribing only | Bulevirtide HEPCLUDEX® |
|
Formulary
|
Powder for solution for injection 2mg
|
|
NICE TA896: Bulevirtide for treating chronic hepatitis D |
|
|
| Entecavir |
|
Formulary
|
Tablets 500micrograms, 1mg |
|
NICE TA153: Entecavir for the treatment of chronic hepatitis B |
|
|
Specialist prescribing onlyLinks
- Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption
Blackpool Teaching Hospitals: Antimicrobial Formulary- Blackpool, Fylde and Wyre Primary Care: Summary of Antimicrobial Prescribing Guidance – Managing Common Infections
- British Association for Sexual Health and HIV
- Dapsone for the treatment of Dermatitis Herpetiformis, other dermatoses and Vasculitis shared care guideline
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Greater Preston, Chorley and South Ribble/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG Recurrent UTI Prophylactic Antibiotic Pathway
- MHRA Drug Safety Update: Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone
- MHRA Drug Safety Update: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone
- MHRA Drug Safety Update:Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone
- MHRA: Baricitinib (Olumiant▼): increased risk of diverticulitis, particularly in patients with risk factors
- MHRA: Baricitinib (Olumiant▼): risk of venous thromboembolism
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation
- MHRA: Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes
- MHRA: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR
- MHRA: Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality
- MHRA: Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir
- MHRA: predicting sepsis, worsening liver function & mortality with boceprevir & telaprevir
- MHRA: predictive factors for sepsis, worsening liver function & mortality with boceprevir & telaprevir
- MHRA: Simeprevir with sofosbuvir: risk of severe bradycardia and heart block when taken with amiodarone
- MHRA: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone
- MHRA: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- NHS England Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
- NICE CG165: Hepatitis B (chronic) - incorporates TA96
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE CG165:Hepatitis B (chronic): diagnosis and management
- NICE CG97: Lower urinary tract symptoms in men: management
- NICE ES27: COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
- NICE Guidance 2012
- NICE NG109: Urinary tract infection (lower): antimicrobial prescribing
- NICE NG112: Urinary tract infection (recurrent): antimicrobial prescribing
- NICE NG113: Urinary tract infection (catheter-associated): antimicrobial prescribing
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG191 COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE TA1056: Molnupiravir for treating COVID-19
- NICE TA1056: Molnupiravir for treating COVID-19
- NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
- NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
- NICE TA153: Entecavir for the treatment of chronic hepatitis B
- NICE TA153: Entecavir for the treatment of chronic hepatitis B
- NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
- NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
- NICE TA330 Sofosbuvir for treating chronic hepatitis C
- NICE TA330: Sofosbuvir for treating chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA896: Bulevirtide for treating chronic hepatitis D
- NICE TA896:Bulevirtide for treating chronic hepatitis D
- NICE TA900:Tixagevimab plus cilgavimab for preventing COVID-19
- NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
- NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
- NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
- NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
- Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older).
- TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023